REJUVENRX Trademark

Trademark Overview

On Monday, January 4, 2021, a trademark application was filed for REJUVENRX with the United States Patent and Trademark Office. The USPTO has given the REJUVENRX trademark a serial number of 90446720. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, March 18, 2025. This trademark is owned by RejuvenRx Inc.. The REJUVENRX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory muscle diseases and disorders, and central nervous system diseases and disorders, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease

Development of pharmaceutical preparations and medicines
rejuvenrx

General Information

Serial Number90446720
Word MarkREJUVENRX
Filing DateMonday, January 4, 2021
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, March 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 18, 2025

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory muscle diseases and disorders, and central nervous system diseases and disorders, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease
Goods and ServicesDevelopment of pharmaceutical preparations and medicines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 2, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, April 2, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRejuvenRx Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H3T1J4
CA
Party NameRejuvenRx Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H3T1J4
CA

Trademark Events

Event DateEvent Description
Thursday, January 7, 2021NEW APPLICATION ENTERED
Friday, April 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 13, 2021ASSIGNED TO EXAMINER
Tuesday, July 27, 2021SUSPENSION LETTER WRITTEN
Tuesday, July 27, 2021LETTER OF SUSPENSION E-MAILED
Tuesday, July 27, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, February 11, 2022SUSPENSION INQUIRY WRITTEN
Friday, February 11, 2022INQUIRY TO SUSPENSION E-MAILED
Friday, February 11, 2022NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, July 26, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, August 20, 2022ASSIGNED TO LIE
Saturday, August 20, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, August 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 26, 2022SUSPENSION LETTER WRITTEN
Friday, August 26, 2022LETTER OF SUSPENSION E-MAILED
Friday, August 26, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, March 30, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, May 4, 2023SUSPENSION LETTER WRITTEN
Thursday, May 4, 2023LETTER OF SUSPENSION E-MAILED
Thursday, May 4, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 4, 2023SUSPENSION INQUIRY WRITTEN
Thursday, May 4, 2023INQUIRY TO SUSPENSION E-MAILED
Thursday, May 4, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, July 28, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, July 29, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, July 29, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 7, 2023SUSPENSION LETTER WRITTEN
Monday, August 7, 2023LETTER OF SUSPENSION E-MAILED
Monday, August 7, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, February 12, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Saturday, March 16, 2024SUSPENSION INQUIRY WRITTEN
Saturday, March 16, 2024INQUIRY TO SUSPENSION E-MAILED
Saturday, March 16, 2024NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, June 10, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, June 11, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 11, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 14, 2024LETTER OF SUSPENSION E-MAILED
Friday, June 14, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, June 14, 2024SUSPENSION LETTER WRITTEN
Tuesday, February 4, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Saturday, February 8, 2025SUSPENSION INQUIRY WRITTEN
Saturday, February 8, 2025INQUIRY TO SUSPENSION E-MAILED
Saturday, February 8, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, February 18, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, February 19, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 19, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, February 22, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 24, 2025LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 12, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 18, 2025PUBLISHED FOR OPPOSITION
Tuesday, March 18, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

rejuvenrx diseases disorders preparations pharmaceutical cerebral alzheimer epilepsy parkinson medicines development